Omkar S, Mitchem M, Hoskins J, Shrader C, Kline J, Nitika
PLoS Genet. 2024; 20(12):e1011338.
PMID: 39652584
PMC: 11658694.
DOI: 10.1371/journal.pgen.1011338.
Saber S, Abdelhady R, Elhemely M, Elmorsy E, Hamad R, Abdel-Reheim M
Front Pharmacol. 2024; 15:1475998.
PMID: 39564119
PMC: 11573589.
DOI: 10.3389/fphar.2024.1475998.
Sollars V, Chapman A, Liang N, Myers S
J Breast Cancer Res. 2024; 4(1):5-10.
PMID: 39363892
PMC: 11448696.
DOI: 10.46439/breastcancer.4.021.
Pinzi L, Belluti S, Piccinini I, Imbriano C, Rastelli G
Pharmaceuticals (Basel). 2024; 17(8).
PMID: 39204176
PMC: 11357446.
DOI: 10.3390/ph17081072.
Omkar S, Shrader C, Hoskins J, Kline J, Mitchem M, Nitika
bioRxiv. 2024; .
PMID: 38915721
PMC: 11195281.
DOI: 10.1101/2024.06.13.598777.
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.
Song B, Yang P, Zhang S
Cancer Commun (Lond). 2024; 44(3):297-360.
PMID: 38311377
PMC: 10958678.
DOI: 10.1002/cac2.12520.
Identification of Novel Natural Dual HDAC and Hsp90 Inhibitors for Metastatic TNBC Using e-Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Studies.
Abdelmoniem N, Abdallah M, Mukhtar R, Moutasim F, Rafie Ahmed A, Edris A
Molecules. 2023; 28(4).
PMID: 36838758
PMC: 9965823.
DOI: 10.3390/molecules28041771.
Advances in the Mechanistic Study of the Control of Oxidative Stress Injury by Modulating HDAC6 Activity.
Xue Y, Gan B, Zhou Y, Wang T, Zhu T, Peng X
Cell Biochem Biophys. 2023; 81(1):127-139.
PMID: 36749475
PMC: 9925596.
DOI: 10.1007/s12013-022-01125-w.
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma.
Garcha H, Nawar N, Sorger H, Erdogan F, Aung M, Sedighi A
Pharmaceuticals (Basel). 2022; 15(11).
PMID: 36355493
PMC: 9692247.
DOI: 10.3390/ph15111321.
Colony Formation Assay to Test the Impact of HDACi on Leukemic Cells.
Pons M, Beyer M
Methods Mol Biol. 2022; 2589:17-25.
PMID: 36255615
DOI: 10.1007/978-1-0716-2788-4_2.
AR12 increases BAG3 expression which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy.
Dent P, Booth L, Roberts J, Poklepovic A, Martinez J, Cridebring D
Aging (Albany NY). 2022; 14(20):8221-8242.
PMID: 36227739
PMC: 9648812.
DOI: 10.18632/aging.204337.
HDAC6: A unique HDAC family member as a cancer target.
Kaur S, Rajoria P, Chopra M
Cell Oncol (Dordr). 2022; 45(5):779-829.
PMID: 36036883
DOI: 10.1007/s13402-022-00704-6.
The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention.
Alseksek R, Ramadan W, Saleh E, El-Awady R
Int J Mol Sci. 2022; 23(15).
PMID: 35897717
PMC: 9331760.
DOI: 10.3390/ijms23158141.
HDAC6 is a prognostic biomarker that mediates IL-13 expression to regulate macrophage polarization through AP-1 in oral squamous cell carcinoma.
Tseng C, Huang S, Tsai H, Wu C, Hsieh T
Sci Rep. 2022; 12(1):10513.
PMID: 35732647
PMC: 9217956.
DOI: 10.1038/s41598-022-14052-w.
Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases.
Li J, Yu M, Fu S, Liu D, Tan Y
Front Pharmacol. 2022; 13:907981.
PMID: 35652048
PMC: 9149003.
DOI: 10.3389/fphar.2022.907981.
Functional stratification of cancer drugs through integrated network similarity.
Unsal-Beyge S, Tuncbag N
NPJ Syst Biol Appl. 2022; 8(1):11.
PMID: 35440787
PMC: 9018743.
DOI: 10.1038/s41540-022-00219-8.
MicroRNA-22 represses glioma development via activation of macrophage-mediated innate and adaptive immune responses.
Tu J, Fang Y, Han D, Tan X, Xu Z, Jiang H
Oncogene. 2022; 41(17):2444-2457.
PMID: 35279703
DOI: 10.1038/s41388-022-02236-7.
Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors.
Sedky N, Hamdan A, Emad S, Allam A, Ali M, Tolba M
Clin Transl Oncol. 2022; 24(7):1262-1273.
PMID: 35066777
DOI: 10.1007/s12094-022-02779-x.
Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis.
Lai C, Xie C, Raufman J, Xie G
Cancers (Basel). 2022; 14(1).
PMID: 35008383
PMC: 8750794.
DOI: 10.3390/cancers14010219.
Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3.
Wachholz V, Mustafa A, Zeyn Y, Henninger S, Beyer M, Dzulko M
Arch Toxicol. 2021; 96(1):177-193.
PMID: 34665271
PMC: 8748367.
DOI: 10.1007/s00204-021-03174-1.